3Chopt Investment Partners LLC Makes New $565,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

3Chopt Investment Partners LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 538 shares of the biopharmaceutical company’s stock, valued at approximately $565,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after acquiring an additional 91,956 shares in the last quarter. Capital World Investors increased its position in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after acquiring an additional 23,146 shares during the last quarter. Capital International Investors raised its holdings in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares in the last quarter. Putnam Investments LLC grew its stake in Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after purchasing an additional 24,329 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on REGN. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada reduced their target price on shares of Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating for the company in a research report on Tuesday, September 24th. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Argus lifted their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,118.62.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders have sold a total of 8,033 shares of company stock worth $9,399,345 in the last ninety days. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,051.24 on Tuesday. The stock has a market cap of $115.83 billion, a PE ratio of 31.06, a PEG ratio of 3.57 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm’s fifty day moving average price is $1,128.54 and its two-hundred day moving average price is $1,036.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the firm posted $8.79 earnings per share. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.